Literature DB >> 1775173

Identification of paramyosin as a potential protective antigen against Brugia malayi infection in jirds.

B W Li1, R Chandrashekar, R M Alvarez, F Liftis, G J Weil.   

Abstract

Vaccination of jirds with irradiated infective larvae of Brugia malayi has been reported to provide partial immunity to larval challenge. In the present study, we found that sera from vaccinated animals recognized larval antigens with apparent molecular weights of 97, 55-60, and 10 kDa that were not recognized by sera from infected animals. A B. malayi cDNA expression library in lambda gt11 was screened to identify clones that were preferentially recognized by sera from immunized animals. One of these clones (BM-5) was chosen for further study. BM-5 contains a 2.1 kb DNA insert and produces a fusion protein with a molecular weight of 185 kDa. Antibody, affinity-purified with the BM-5 fusion protein, binds to a 97 kDa native B. malayi antigen. Immunological studies and partial DNA sequence data confirm that BM-5 encodes paramyosin. Recombinant B. malayi paramyosin is strongly recognized by antibodies in sera from jirds that have been immunized either by injection with irradiated larvae or by chemotherapy-abbreviated infection. Most sera from infected jirds do not contain antibody to paramyosin. Additional studies are needed to determine whether paramyosin is actually protective in this filariasis model.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1775173     DOI: 10.1016/0166-6851(91)90075-h

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  12 in total

Review 1.  A comprehensive, model-based review of vaccine and repeat infection trials for filariasis.

Authors:  C Paul Morris; Holly Evans; Sasha E Larsen; Edward Mitre
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

2.  The abundant larval transcript-1 and -2 genes of Brugia malayi encode stage-specific candidate vaccine antigens for filariasis.

Authors:  W F Gregory; A K Atmadja; J E Allen; R M Maizels
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

3.  The immunodominant Brugia malayi paramyosin as a marker of current infection with Wuchereria bancrofti adult worms.

Authors:  S Langy; C Plichart; P Luquiaud; S A Williams; L Nicolas
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

4.  Codon usage and gene organization in Brugia.

Authors:  M P Hammond
Journal:  Parasitol Res       Date:  1994       Impact factor: 2.289

5.  Troponin 1 of human filarial parasite Brugia malayi: cDNA cloning, expression, purification, and its immunoprophylactic potential.

Authors:  Vikas Kushwaha; Prachi Tewari; Payal Mandal; Anurag Tripathi; P Kalpana Murthy
Journal:  Parasitol Res       Date:  2019-05-04       Impact factor: 2.289

6.  Paramyosin of Echinococcus granulosus: cDNA sequence and characterization of a tegumental antigen.

Authors:  F Mühlschlegel; L Sygulla; P Frosch; P Massetti; M Frosch
Journal:  Parasitol Res       Date:  1993       Impact factor: 2.289

7.  Onchocerca volvulus larval antigen, OvB20, induces partial protection in a rodent model of onchocerciasis.

Authors:  M J Taylor; N Abdel-Wahab; Y Wu; R E Jenkins; A E Bianco
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

8.  Molecular cloning, purification and characterisation of myosin of human lymphatic filarial parasite Brugia malayi.

Authors:  S K Verma; I Bansal; S Vedi; J K Saxena; V M Katoch; S M Bhattacharya
Journal:  Parasitol Res       Date:  2007-12-07       Impact factor: 2.289

9.  Host protective immunity and vaccine development studies in lymphatic filariasis.

Authors:  M V Reddy; R Alli; B C Harinath
Journal:  Indian J Clin Biochem       Date:  2000-08

10.  Transcriptomes and pathways associated with infectivity, survival and immunogenicity in Brugia malayi L3.

Authors:  Ben-Wen Li; Amy C Rush; Makedonka Mitreva; Yong Yin; David Spiro; Elodie Ghedin; Gary J Weil
Journal:  BMC Genomics       Date:  2009-06-15       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.